In this review:
TCZ vs TNFi as first-line bDMARDs in RA: efficacy + retention rates
Comparative effectiveness of TNFi vs non-TNFi in RA
Baseline comorbidities affect PsA treatment outcomes
Early diagnosis and treatment improves RA outcomes
Nailfold videocapillaroscopy: a role in very early diagnosis of SSc?
Ixekizumab shows promise in active PsA
Use TNFi to induce remission in early SpA?
Tofacitinib + oral synthetic DMARD: efficacious, safe in PsA
Certolizumab pegol: sustained MRI improvements in AS, nr-axSpA
Co-existing fibromyalgia may impact RA disease activity
Please login below to download this issue (PDF)